This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva must delist five unlawful inhaler patents in US FDA's Orange Book, judge says

( June 10, 2024, 23:28 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals must correct or delete five patents for asthma inhalers listed in a US Federal Drug Administration registry known as the Orange Book, a New Jersey federal judge said in an order granting Amneal Pharmaceuticals' motion for partial judgment on the pleadings in a patent infringement dispute. "This Court finds ... in short, that the Inhaler Patents do not claim the drug for which the applicant submitted the application," US District Judge Stanley Chesler said.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections